Belgia - engleză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

correvio - tirofiban hydrochloride 56,18 µg/ml - eq. tirofiban 50 µg/ml - solution for infusion - 0,05 mg/ml - tirofiban hydrochloride 56.18 µg/ml - tirofiban

Canada - engleză - Health Canada

correvio (uk) ltd - tirofiban (tirofiban hydrochloride) - liquid - 0.25mg - tirofiban (tirofiban hydrochloride) 0.25mg - platelet aggregation inhibitors

Canada - engleză - Health Canada

cipher pharmaceuticals inc - tirofiban (tirofiban hydrochloride) - solution - 12.5mg - tirofiban (tirofiban hydrochloride) 12.5mg - platelet aggregation inhibitors

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

diapharm gmbh & co. kg - ibuprofen; pseudoephedrine hydrochloride - film-coated tablet - 200/30 milligram(s) - other cold preparations

Australia - engleză - Department of Health (Therapeutic Goods Administration)

correvio australia pty ltd - tirofiban hydrochloride, quantity: 0.0562 mg/ml (equivalent: tirofiban, qty 0.05 mg/ml) - injection, solution - excipient ingredients: sodium chloride; sodium citrate dihydrate; citric acid; sodium hydroxide; hydrochloric acid; water for injections - aggrastat, in combination with heparin, is indicated for patients with unstable angina or non-q-wave myocardial infarction to prevent cardiac ischaemic events.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

correvio australia pty ltd - tirofiban hydrochloride, quantity: 0.0562 mg/ml (equivalent: tirofiban, qty 0.05 mg/ml) - injection, solution - excipient ingredients: sodium hydroxide; citric acid; water for injections; sodium citrate dihydrate; sodium chloride; hydrochloric acid - aggrastat, in combination with heparin, is indicated for patients with unstable angina or non-q-wave myocardial infarction to prevent cardiac ischaemic events.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

medicure international inc - tirofiban hydrochloride (unii: 6h925f8o5j) (tirofiban - unii:ggx234si5h) - aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-st elevation acute coronary syndrome (nste-acs). aggrastat is contraindicated in patients with: - severe hypersensitivity reaction to aggrastat (i.e., anaphylactic reactions) [see adverse reactions (6.2)] . - a history of thrombocytopenia following prior exposure to aggrastat [see adverse reactions (6.1)] . - active internal bleeding or a history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month [see adverse reactions (6.1) ]. risk summary while published data cannot definitively establish the absence of risk, available published case reports have not established an association with tirofiban use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes. untreated myocardial infarction can be fatal to the pregnant woman and f

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

correvio (uk) ltd - tirofiban hydrochloride monohydrate - concentrate for soln for inf - 250 microgram/ml

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

correvio (uk) ltd - tirofiban hydrochloride monohydrate - concentrate for soln for inf - 50 microgram/ml

Singapore - engleză - HSA (Health Sciences Authority)

dch auriga singapore - tirofiban hydrochloride monohydrate - injection - 0.281 mg/ml - tirofiban hydrochloride monohydrate 0.281 mg/ml